Tekla Life Sciences Investors
NYSE:HQLAsset Management
+$0.11 today
- Market cap
- $585.96M
- Beta
- 0.73
- P/E (TTM)
- 2.8
- EPS (TTM)
- $6.52
- Dividend yield
- 11.35%
Volume 0.12M
Average 0.11M
HQL Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Tekla Life Sciences InvestorsNYSE: HQL
Other Working Capital · Q2 FY2026 · quarter ended Mar 2026
Other working capital grows 138.9% year over year
Q2 FY2026 other working capital of $154.72K rose 138.9% year over year.
Context
- Other working capital amounted to 0.3% of revenue in FY2025.
- Other working capital increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (262.64K) USD
- Year-over-year change
- —
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (262.64K) | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
| FY2021 | 2021-09-30 | 0 | — |
| FY2020 | 2020-09-30 | 0 | — |
Other Working Capital vs competitors
How HQL compares with its peers on the latest reported figures
- HQL's FY2025 other working capital of $262.64K is the 8th largest of the 10 companies compared; the peer median is $246.9K.
- Other working capital amounts to 0.3% of revenue for HQL, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $55.47M | -671.9% | -37.6% | 37.6% | |
| LTM Jun 2025 | $18.96M | -738.6% | -39.6% | 46.2% | |
| LTM Mar 2026 | $5.71M | +1183.3% | — | 8.1% | |
| LTM Mar 2026 | $1.89M | +59.4% | +7.8% | 1.5% | |
| LTM Mar 2026 | $1.69M | -48.1% | — | 2.1% | |
| LTM Mar 2026 | $1.37M | -83.1% | +43.2% | 5.6% | |
| LTM Mar 2026 | $898K | -54.9% | +472.2% | 0.8% | |
| FY2025 | $262.64K | — | — | 0.3% | |
| LTM Dec 2025 | $246.9K | -107.6% | — | 0.1% | |
| FY2024 | $0 | — | — | 0.0% | |
| Peer median (excluding HQL) | $246.9K | -69.0% | +7.8% | 2.1% | |
Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Sep 2020 | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | 123.05K | 64.53K | (104.6K) | 22.35M | 85.59M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 0 | 0 | 0 | 0 | (203.41K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 59.23K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 0 | 0 | 0 | 0 | (262.64K) |
| Other Non-Cash Items | (123.05K) | (64.53K) | 104.6K | (22.35M) | (87.71M) |
| Operating Cash Flow | 0 | 0 | 0 | 0 | (2.32M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (5) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (314.13M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 339.34M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 25.21M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (31.63M) |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 0 | 0 | 0 | (31.63M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 8.81M |
| Net Change in Cash | 0 | 990 | (545) | 32 | 75.54K |
| Free Cash Flow | 0 | 0 | 0 | 0 | (2.32M) |
Tekla Life Sciences Investors
NYSE:HQL
Intrinsic Alpha fair value
Locked
Current Price
$19.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.